Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients

M. Milone, X. M. Shen, D. Selcen, K. Ohno, J. Brengman, S. T. Iannaccone, C. M. Harper, A. G. Engel

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. Methods: Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. Results: In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. Conclusions: All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype- genotype correlation except for an E-box mutation associated with jaw deformities.

Original languageEnglish (US)
Pages (from-to)228-235
Number of pages8
JournalNeurology
Volume73
Issue number3
DOIs
StatePublished - Jul 21 2009

Fingerprint

Muscle Weakness
Mutation
Cholinergic Receptors
Genetic Association Studies
peripheral membrane protein 43K
Congenital Myasthenic Syndromes
Ophthalmoplegia
Cholinergic Agonists
Nonsense Codon
Missense Mutation
Secondary Prevention
Jaw
Cholinergic Agents
Early Diagnosis
Extremities

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Myasthenic syndrome due to defects in rapsyn : Clinical and molecular findings in 39 patients. / Milone, M.; Shen, X. M.; Selcen, D.; Ohno, K.; Brengman, J.; Iannaccone, S. T.; Harper, C. M.; Engel, A. G.

In: Neurology, Vol. 73, No. 3, 21.07.2009, p. 228-235.

Research output: Contribution to journalArticle

Milone, M, Shen, XM, Selcen, D, Ohno, K, Brengman, J, Iannaccone, ST, Harper, CM & Engel, AG 2009, 'Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients', Neurology, vol. 73, no. 3, pp. 228-235. https://doi.org/10.1212/WNL.0b013e3181ae7cbc
Milone, M. ; Shen, X. M. ; Selcen, D. ; Ohno, K. ; Brengman, J. ; Iannaccone, S. T. ; Harper, C. M. ; Engel, A. G. / Myasthenic syndrome due to defects in rapsyn : Clinical and molecular findings in 39 patients. In: Neurology. 2009 ; Vol. 73, No. 3. pp. 228-235.
@article{da25030a086c4c40815aeb4d5e192cfc,
title = "Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients",
abstract = "Background: Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. Methods: Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. Results: In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. Conclusions: All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype- genotype correlation except for an E-box mutation associated with jaw deformities.",
author = "M. Milone and Shen, {X. M.} and D. Selcen and K. Ohno and J. Brengman and Iannaccone, {S. T.} and Harper, {C. M.} and Engel, {A. G.}",
year = "2009",
month = "7",
day = "21",
doi = "10.1212/WNL.0b013e3181ae7cbc",
language = "English (US)",
volume = "73",
pages = "228--235",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Myasthenic syndrome due to defects in rapsyn

T2 - Clinical and molecular findings in 39 patients

AU - Milone, M.

AU - Shen, X. M.

AU - Selcen, D.

AU - Ohno, K.

AU - Brengman, J.

AU - Iannaccone, S. T.

AU - Harper, C. M.

AU - Engel, A. G.

PY - 2009/7/21

Y1 - 2009/7/21

N2 - Background: Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. Methods: Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. Results: In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. Conclusions: All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype- genotype correlation except for an E-box mutation associated with jaw deformities.

AB - Background: Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. Methods: Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. Results: In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. Conclusions: All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype- genotype correlation except for an E-box mutation associated with jaw deformities.

UR - http://www.scopus.com/inward/record.url?scp=68949173752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949173752&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181ae7cbc

DO - 10.1212/WNL.0b013e3181ae7cbc

M3 - Article

C2 - 19620612

AN - SCOPUS:68949173752

VL - 73

SP - 228

EP - 235

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -